|
Melanoma, B16
|
0.080 |
Biomarker
|
disease |
BEFREE |
Here we demonstrate that, although mice lacking all receptors for the Fc part of IgG (FcγRs) develop normal IgG responses after MCMV-TRP2 vaccination, the protection against B16 melanoma was completely abrogated, indicating that FcγRs are indispensable in the downstream effector pathway of the polyclonal anti-TRP2 antibody response.
|
30034625 |
2018 |
|
Melanoma, B16
|
0.080 |
Biomarker
|
disease |
BEFREE |
SLA individually or mixed with uncharged glyolipid (lactosylarchaeol, LA) constituted efficacious carrier vesicles for entrapped antigens (ovalbumin or melanoma associated tyrosinase-related protein 2 [TRP-2]) and induction of strong cell-mediated responses in mice and protection against subsequent B16 melanoma tumor challenge.
|
28537465 |
2017 |
|
Melanoma, B16
|
0.080 |
Biomarker
|
disease |
BEFREE |
After biolistic DNA vaccination with plasmids encoding the TRP2 gene we observed the induction of TRP2-specific T-cells and antibodies associated with vitiligo-like fur depigmentation and tumor immunity against B16 melanoma cells.
|
23104352 |
2013 |
|
Melanoma, B16
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
DC-shA20-FAP-TRP2 vaccination induced robust FAP- and TRP2-specific T-cell responses, resulting in greater antitumor activity in the B16 melanoma model in comparison to monovalent vaccines or a vaccine encoding antigens and a control shRNA.
|
24349329 |
2013 |
|
Melanoma, B16
|
0.080 |
Biomarker
|
disease |
BEFREE |
The results show that combination immunotherapy consisting of vaccination with a synthetic peptide corresponding to an immunodominant CTL epitope derived from tyrosinase-related protein-2 administered with CpG-ODN adjuvant and followed by systemic injection of anti-CTLA-4 antibodies increased the survival of mice against the poorly immunogenic B16 melanoma.
|
12810660 |
2003 |
|
Melanoma, B16
|
0.080 |
Biomarker
|
disease |
BEFREE |
In this study, we tested the efficacy of adenoviral vectors encoding human gp100 (Ad2/hugp100), murine gp100 (Ad2/mugp100), or murine TRP-2 (Ad2/muTRP-2) for their ability to elicit a specific cellular immune response and inhibit the growth of B16 melanoma tumor cells in the mouse.
|
10933943 |
2000 |
|
Melanoma, B16
|
0.080 |
Biomarker
|
disease |
BEFREE |
Genetic immunization of mice with human TRP2 resulted in coat depigmentation as a sign of autoimmune-mediated destruction of melanocytes and provided significant protection against metastatic growth of B16 melanoma Induction of protective immunity was associated with TRP2-reactive antibodies and CD8+ T cells.
|
10728600 |
2000 |
|
Melanoma, B16
|
0.080 |
Biomarker
|
disease |
BEFREE |
Of perhaps greater clinical interest, genetic immunization using cDNA encoding the normal, germline-encoded murine melanosomal protein tyrosinase-related protein-2 (TRP-2) resulted in delayed outgrowth of TRP-2+ B16 melanoma in mice and was associated with an in vivo activation of TRP-2-specific cytotoxic T lymphocytes.
|
10078966 |
1999 |